Market Overview

Lumicell Expands Board with Addition of Michael Ruettgers

Share:

Industry executive with history of building successful Boston-based
businesses will serve as an advisor to the development of Lumicell's
growth and long-term business strategies

Lumicell, Inc., an innovation leader in molecular imaging within
healthcare focused in cancer, perfusion, wound care and infection, today
announced the addition of Michael Ruettgers to its Board of Directors.

"We are excited to add Mike's leadership to our board. He knows how to
build winning teams and has experience in bringing quality products and
services to life," said Andrey Zarur, Chairman Board of Directors,
Lumicell. "His decades of experience in scaling global businesses – and
in healthcare, technology and regulatory issues – will help us think
bigger and drive long-term growth."

"I'm thrilled to play a role in Lumicell's growth," said Ruettgers.
"It's important get the company's groundbreaking technology into the
hands of physicians where it can improve patient outcomes and reduce
healthcare costs. It's exhilarating to work with growing companies like
Lumicell, as they have the potential for the largest amount of growth
and industry impact. The company's core technologies will benefit
patients and physicians, healthcare practices, support the company, and
encourage stakeholders."

Ruettgers, also known as Mike, is a retired special advisor to EMC
Corporation, where he previously held leadership roles including
executive chairman of the board, CEO and president. Under Mike's
leadership, EMC became the global leader in the storage network market,
became one of the fastest growing companies in the United States and
achieved the highest single-decade performance (1990-2000) of any listed
stock in the history of the New York Stock Exchange. Mike left his
leadership role formally in the mid 2000s with over $23B in revenue and
24,000 employees.

Ruettgers currently sits on the Board of Trustees of Lahey Clinic, on
the Executive Committee of the Board of Trustees of Holy Cross College,
the Board of Virsec Systems and Foreground Systems and is a member of
the Massachusetts Business Roundtable, the Massachusetts High Tech
Council, and Business for Better Schools.

A frequent author on key policy and technology issues, Ruettgers was
named one of the World's Top 25 Executives by BusinessWeek; one of the
Best Chief Executive Officers in America by Worth magazine; one of the
25 Most Powerful People in Networking in 2000 by Network World; and
Chief Executive Officer of the Year for 2000 by Massachusetts Investor's
Digest. He holds a BS from Idaho State University and an MBA from
Harvard Business School.

"Throughout his career, Mike has built an exceptional reputation in
successfully growing and leading companies. His expertise will raise the
team's sights toward becoming the global leader in precision medical
imaging," said Dave Furneaux, lead investor, CEO of BlueIO and Managing
Partner of Kodak Venture Partners. "We are delighted to have Mike's
leadership on Lumicell's board and look forward to his guidance bringing
exceptional value to the development of Lumicell."

About Lumicell, Inc.
Lumicell is a technology leader in the
field of image-guided cancer surgery. The company is developing a novel
system that enables real-time detection of tumor tissue in patients so
that no cancer cells are left behind during surgery. The company's LUM
System has unprecedented ability to see and remove cancer cells
remaining in the surgical cavity – beyond the margin of the specimen –
and has the potential to significantly improve surgical outcomes and
reduce healthcare costs by eliminating the need for repeat surgeries.
Lumicell is investigating the LUM System in patients undergoing surgery
for breast cancer, ovarian cancer, prostate cancer, brain cancer,
colorectal, esophageal and pancreatic cancers. Additional future
indications are planned to include perfusion, wound care and infection
and surgeries for lung and liver cancer. For more information, please
visit www.lumicell.com.

View Comments and Join the Discussion!